{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:25:16Z","timestamp":1787235916889,"version":"build-2736575974"},"reference-count":92,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Merck Sharp & Dohme LLC"},{"name":"Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.1080\/14737167.2026.2634755","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:13:24Z","timestamp":1772709204000},"page":"429-441","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024\u20132033"],"prefix":"10.1080","volume":"26","author":[{"given":"Gittan","family":"Blezer","sequence":"first","affiliation":[{"name":"Lumanity","place":["Utrecht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Patterson","sequence":"additional","affiliation":[{"name":"Lumanity","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"MI\u010doch","sequence":"additional","affiliation":[{"name":"MSD","place":["Prague, Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Alahakoon","sequence":"additional","affiliation":[{"name":"MSD","place":["Prague, Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Lai","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Khurana","sequence":"additional","affiliation":[{"name":"MSD Sharp & Dohme GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aguiar-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Merck Canada Inc","place":["Kirkland, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"OECD\/European Commission. EU country cancer profile: czechia 2025. Paris: The Organisation for Economic Co-operation and Development (OECD) and the European Commission; 2025."},{"key":"e_1_3_7_4_1","unstructured":"Eurostat. Death due to cancer by sex 2022. Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/TPS00116\/default\/table?lang=en&category=hlth.hlth_cdeath.hlth_cd_gmor"},{"key":"e_1_3_7_5_1","unstructured":"National cancer control plan 2030. Ministry of health of the Czech Republic. 2022. Available from: https:\/\/iccp-portal.org\/plans\/czech-national-cancer-control-plan-2030-english-version"},{"key":"e_1_3_7_6_1","unstructured":"European Commission. Europe\u2019s beating cancer plan: communication from the commission to the European parliament and the council 2022. Available from: https:\/\/health.ec.europa.eu\/system\/files\/2022-02\/eu_cancer-plan_en_0.pdf"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10680-017-9456-y"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.14735\/amko2014406"},{"key":"#cr-split#-e_1_3_7_9_1.1","unstructured":"National Cancer Institute. Age and Cancer Risk. 2025 [Updated 2025 May 2"},{"key":"#cr-split#-e_1_3_7_9_1.2","unstructured":"cited 2025 Nov 13]. Available from: https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/age"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00646-0"},{"key":"e_1_3_7_11_1","unstructured":"Czech Republic Ministry of Health. Czech National cancer control plan. 2030 [In Czech]. Available from: https:\/\/planobnovy.gov.cz\/"},{"key":"e_1_3_7_12_1","unstructured":"Institute of Health Information and Statistics of the Czech Republic (IHIS CR) and Faculty of Medicine of Masaryk University. Portal of neoplasm epidemiology in the Czech Republic 2024. Available from: https:\/\/www.svod.cz\/en\/"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.57334"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e2"},{"key":"e_1_3_7_16_1","unstructured":"State Institute for Drug Control in the Czech Republic. Drug Overview [In Czech]. Available from: https:\/\/prehledy.sukl.cz\/prehled_leciv.html#\/"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01599"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.707214"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030526"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.028"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02355"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1546447"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1575813"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2436342"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00328-4"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1"},{"key":"e_1_3_7_35_1","volume-title":"Impact on health and productivity outcomes of anti-PD-(L)1 agents to treat early-stage cancers in Italy","author":"Marcellusi A","year":"2024","unstructured":"Marcellusi A, Calabr\u00f2 F, Di Giacomo AM, et al., editors. Impact on health and productivity outcomes of anti-PD-(L)1 agents to treat early-stage cancers in Italy [Poster]. Rome, Italy: ISPOR Italy-Rome Chapter; 2024 Dec 4\u20135."},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00357-z"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601377"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613120"},{"key":"e_1_3_7_39_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab plus chemotherapy for untreated triple-negative locally recurrent unresectable or metastatic breast cancer. 2022 [cited 2026 Jan 19]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta801"},{"key":"e_1_3_7_40_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma 2022. [cited 2026 Jan 19]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta766\/resources\/pembrolizumab-for-adjuvant-treatment-of-completely-resected-stage-3-melanoma-pdf-82611439262917"},{"key":"e_1_3_7_41_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. 2022 [cited 2026 Jan 19]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta837"},{"key":"e_1_3_7_42_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of renal cell carcinoma 2022. [cited 2026 Jan 19]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta830"},{"key":"e_1_3_7_43_1","unstructured":"State Institute for Drug Control in the Czech Republic. Cost-effectiveness analysis critical appraisal procedure 2017. Available from: https:\/\/sukl.gov.cz\/file\/89740_1_2\/"},{"key":"e_1_3_7_44_1","unstructured":"Burcin B Kucera T. Population development forecast of the Czech Republic for the period 2008\u20132070. [In Czech]. 2010. Available from: https:\/\/www.mpsv.cz\/documents\/20142\/225485\/prognoza_2010.pdf\/15e1e812-d17a-5f46-8d35-56da8642227d"},{"key":"e_1_3_7_45_1","unstructured":"Czech Statistical Office. Population structure and projection [in Czech] 2023. Available from: https:\/\/csu.gov.cz\/pocet-struktura-a-projekce-obyvatel?pocet=10&podskupiny=132&razeni=-datumVydani&start=0"},{"key":"e_1_3_7_46_1","first-page":"132","article-title":"Triple negative breast cancer \u2013 prognostically highly severe group of mammary malignancies [in Czech]","volume":"77","author":"Min\u00e1r L","year":"2012","unstructured":"Min\u00e1r L, Hvizdov\u00e1 M, Weinberger V, et al. Triple negative breast cancer \u2013 prognostically highly severe group of mammary malignancies [in Czech]. Czech Gynecology. 2012;77:132\u2013138.","journal-title":"Czech Gynecology"},{"key":"e_1_3_7_47_1","unstructured":"State Institute for Drug control in the Czech Republic. KEYTRUDA [In Czech]. [cited 2025 Nov 13]. Available from: https:\/\/www.sukl.sk\/en\/servis\/search\/searching-on-the-database-of-medicinal-products?page_id=410&lie_nazov=keytruda&atc_nazov=&lie_kod=&atc_kod=&lie_rc=&drz_kod="},{"key":"e_1_3_7_48_1","unstructured":"European Society of Medical Oncology (ESMO). ESMO clinical practice guidelines [cited 2024]. Available from: https:\/\/www.esmo.org\/guidelines\/"},{"key":"e_1_3_7_49_1","unstructured":"Czech social security administration. Available from: https:\/\/www.cssz.cz\/"},{"key":"e_1_3_7_50_1","unstructured":"European Medicines Agency. KEYTRUDA: summary of product characteristics. [cited 2022 May 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"e_1_3_7_51_1","unstructured":"European Medicines Agency. OPDIVO: summary of product characteristics. [cited 2022 May 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf"},{"key":"e_1_3_7_52_1","volume-title":"Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma [TA837]","author":"National Institute for Health and Care Excellence (NICE)","year":"2022","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma [TA837]. National Institute for Health and Care Excellence (NICE); 2022 [cited 2024 Oct 2]."},{"key":"e_1_3_7_53_1","volume-title":"Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma [TA766]","author":"National Institute for Health and Care Excellence (NICE)","year":"2022","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma [TA766]. National Institute for Health and Care Excellence (NICE); 2022 [cited 2024 Oct 2]."},{"key":"e_1_3_7_54_1","volume-title":"Pembrolizumab for adjuvant treatment of renal cell carcinoma [TA830]","author":"National Institute for Health and Care Excellence (NICE)","year":"2022","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for adjuvant treatment of renal cell carcinoma [TA830]. National Institute for Health and Care Excellence (NICE); 2022 [cited 2024 Oct 2]."},{"key":"e_1_3_7_55_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [TA851]. 2022 [cited 2024 Sep 4]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta851"},{"key":"e_1_3_7_56_1","unstructured":"Czech statistical office. Mortality tables 2020\u20132024 [website in Czech]. [cited 2024 Jun]. Available from: https:\/\/csu.gov.cz\/produkty\/umrtnostni-tabulky-5i3aadd1z7"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4500"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.03.016"},{"key":"e_1_3_7_59_1","unstructured":"National Cancer Institute. SEER-Medicare linked data resource. Available from: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/"},{"key":"e_1_3_7_60_1","unstructured":"MSD. Study to evaluate the efficacy and Safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475\u2013426 KEYNOTE-426). Clinicaltrials.gov; [cited 2022 Aug 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02853331"},{"key":"e_1_3_7_61_1","unstructured":"MSD. Study to evaluate the Safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to ipilimumab in participants with advanced melanoma (MK-3475\u2013006 KEYNOTE-006). Clinicaltrials.gov; [cited 2020 Jun 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01866319"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02365-1"},{"key":"e_1_3_7_63_1","unstructured":"MSD. Study of pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma (MK-3475\u2013054 1325-MG KEYNOTE-054). Clinicaltrials.gov. [updated 2023 Aug 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02362594"},{"key":"e_1_3_7_64_1","unstructured":"MSD. Safety and efficacy study of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma Post nephrectomy (MK-3475\u2013564 KEYNOTE-564). clinicaltrials.gov. [updated 2023 Jun 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03142334"},{"key":"e_1_3_7_65_1","unstructured":"MSD. Study of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants with triple negative breast cancer (TNBC) (MK-3475\u2013522 KEYNOTE-522). Clinicaltrial.gov. [Updated 2023 July 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03036488"},{"key":"#cr-split#-e_1_3_7_66_1.1","unstructured":"MSD. Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma (MK-3475-716 KEYNOTE-716). Clinicaltrials.gov [Updated 2024 August 21"},{"key":"#cr-split#-e_1_3_7_66_1.2","unstructured":"cited 2024 Aug 28]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03553836"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.tps8603"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2850"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-85"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.012"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4940"},{"key":"e_1_3_7_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_3_7_79_1","unstructured":"MSD. Tudy of pembrolizumab (MK-3475) plus chemotherapy vs. Placebo plus chemotherapy for Previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (MK-3475\u2013355 KEYNOTE-355). Clinicaltrials.gov [updated 2022 Jul 25]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02819518"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012222"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy201"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3141"},{"key":"e_1_3_7_85_1","unstructured":"Czech social security administration. Retirement age. Available from: https:\/\/www.cssz.cz\/web\/lang\/duchodovy-vek?lang=en"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2023.2275350"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2174748"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.016"},{"key":"e_1_3_7_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01856"},{"key":"e_1_3_7_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00922-6"},{"key":"e_1_3_7_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00142-8"},{"key":"e_1_3_7_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.1459"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2634755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:44:17Z","timestamp":1773661457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2634755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,16]]}},"alternative-id":["10.1080\/14737167.2026.2634755"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2634755","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}